Neurox, 125 mg 30 pcs.

Pharmacotherapeutic group: antioxidant drug.
ATX code: N07XX
Pharmacological properties

Pharmacodynamics
Ethylmethylhydroxypyridine succinate is an inhibitor of free radical processes, membranoprotector with antihypoxic, stress-protective, nootropic, anticonvulsant and anxiolytic action. Ethylmethylhydroxypyridine succinate increases the resistance of the body to various damaging factors (shock, hypoxia, ischemia, cerebral circulation disorders, intoxication by alcohol and antipsychotic drugs (neuroleptics)).
The mechanism of action of ethylmethylhydroxypyridine succinate is due to its antioxidant, antihypoxant and membrane-protective action. It inhibits lipid peroxidation, increases superoxide dismutase activity, increases the lipid-protein ratio, reduces membrane viscosity, increases its

fluidity. Ethylmethylhydroxypyridine succinate modulates the activity of membrane-bound enzymes (calcium independent phosphodiesterase, adenylate cyclase, acetylcholinesterase), receptor complexes (benzodiazepine, gamma-aminobutyric acid, acetylcholine), which increases their binding ability to ligands, helps maintain the structural and functional organization of biomembranes, neurotransport and improve synaptic transmission. Ethylmethylhydroxypyridine succinate increases the content of dopamine in the brain. Causes compensatory activation of aerobic glycolysis and a decrease in the degree of inhibition of oxidative processes in the Krebs cycle in hypoxia with an increase in adenosine triphosphate and creatine phosphate, activation of energy-synthesizing functions of mitochondria, stabilization of cell membranes.
It improves metabolism and blood supply to the brain, improves microcirculation and blood rheology, reduces platelet aggregation. Stabilizes membrane structures of blood cells (erythrocytes and platelets) during hemolysis. It has hypolipidemic action, decreases the total cholesterol and low-density lipoproteins.
Antistressor action is manifested in the normalization of post-stress behavior, somatovegetative disorders, restoration of sleep-wake cycles, disturbed learning and memory processes, reduction of degenerative and morphological changes in the various structures of the brain.
Ethylmethylhydroxypyridine succinate has strong antitoxic effect during withdrawal syndrome. It eliminates neurological and neurotoxic symptoms of acute alcohol intoxication, restores behavioral disorders, vegetative functions. It is also able to eliminate cognitive disorders caused by long-term use of ethanol and its withdrawal. Under the influence of ethylmethylhydroxypyridine succinate the effect of tranquilizing, neuroleptic, antidepressant, sleeping pills and anticonvulsants increases, which allows reducing their doses and side effects. Ethylmethylhydroxypyridine succinate improves functional state of ischemic myocardium. In conditions of coronary insufficiency it increases collateral blood supply of ischemic myocardium, promotes preservation of integrity of cardiomyocytes and maintenance of their functional activity. Effectively restores myocardial contractility in reversible cardiac dysfunction.

Pharmacokinetics
Rapidly absorbed when ingested. Maximum concentration at doses of 400-500 mg is 3.5-4.0 mcg/ml. It is rapidly distributed in organs and tissues. Average retention time in the body when administered orally is 4.9-5.2 h. The drug is metabolized in the liver through glucuron conjugation. Five metabolites were identified: 3-oxypyridine phosphate is formed in liver and with the help of alkaline phosphatase is divided into phosphoric acid and 3-oxypyridine; 2nd metabolite – pharmacologically active, is formed in large amounts and is found in urine 1-2 days after injection; 3rd metabolite is excreted in large amounts with urine; 4th and 5th – glucuron conjugates. T1/2 when administered orally is 2.0-2.6 h. It is rapidly excreted with urine mainly as metabolites and in insignificant amount – unchanged. It is excreted most intensively during the first 4 hours after drug administration. Indexes of urinary excretion of unchanged drug and metabolites have individual variability.

Indications

• After-effects of acute cerebral circulation disorders, including after transient ischemic attacks, in the phase of subcompensation as a preventive course;
• light craniocerebral trauma, consequences of craniocerebral injuries;
• .encephalopathies of various genesis (discirculatory, dysmetabolic, post-traumatic, mixed);
• dietary dystonia syndrome;
• mild cognitive disorders of atherosclerotic genesis;
• anxiety disorders in neurotic and neurosis-like states;
• ischemic heart disease as a part of complex therapy;
• curing withdrawal syndrome in alcoholism with the prevalence of neurotic and vegetative-vascular disorders, postabstinence disorders;
• during withdrawal from alcoholismconditions after acute intoxication with antipsychotic agents;
• asthenic conditions and for the prevention of the development of somatic diseases under the influence of extreme factors and loads;
• impact of extreme (stress) factors.

.

Active ingredient

Ethylmethylhydroxypyridine succinate

Composition

Active ingredient: Ethylmethylhydroxypyridine succinate – 125 mg. Ancillary substances: lactose monohydrate, microcrystalline cellulose 102, potato starch, povidone-K90, croscarmellose sodium, magnesium stearate.

Film coating: Opadray II white 85F48105 (polyvinyl alcohol, macrogol, talc, titanium dioxide).